By Emon Reiser

ImmuCell named Olivier te Boekhorst its next president and chief executive, effective Nov. 1. He will succeed the biotech's longtime leader, Michael Brigham, who has held the role since 2000.

Te Boekhorst is currently the operating partner at Archimed, a global investment firm that backs human and animal healthcare companies. He is also chair of SeqCenter, a DNA sequencing company where he was previously CEO. Te Boekhorst also held several leadership roles at Idexx Laboratories, where he's credited with leading merger and acquisition efforts to consolidate the pet healthcare company's livestock diagnostics segment.

Brigham will stay on as a special adviser to te Boekhorst for at least two months after he assumes the role at the animal health company, and then Brigham will continue to serve on the company's board of directors until its annual meeting. Brigham is subject to re-election by stockholders, the company said.

Immucell said in June it would embark on the CEO succession planning process to replace Brigham, who said at the time that he intended to retire in early 2026.

Write to Emon Reiser at emon.reiser@wsj.com

(END) Dow Jones Newswires

September 29, 2025 16:47 ET (20:47 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.